2 results
Approved WMOCompleted
Our primary objective is to compare the short and medium term (up to 6 months) clinical results in pain and function of the Bauerfeind SecuTec OA brace with only conservative treatment (no brace) in the management of patients with medial knee OA and…
Approved WMORecruiting
To evaluate the efficacy and safety of tucatinib in combination with trastuzumab and mFOLFOX6 in comparison to mFOLFOX6 given with or without either bevacizumab or cetuximab as first-line (1L) treatment in adults with HER2 positive (HER2+)…